Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best performing pharma stocks in 2025. On January 7, Truist raised ...

Teva Pharmaceutical Industries recently reported third-quarter 2025 earnings that exceeded analysts’ expectations, advanced ...

Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related ...

Amneal wins FDA approval for two denosumab biosimilars, expanding lower-cost treatment options for bone loss and cancer patients.

FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving ...

Amneal Pharmaceuticals has just seen its fair value estimate nudged to US$14.00 from US$13.80, a small but meaningful reset that ties directly to how the latest quarterly numbers stack up against ...

In today’s Pharma Pulse, the FDA clears new denosumab biosimilars for osteoporosis and cancer-related bone loss, while ...

Dr Reddy's Laboratories announced that its wholly owned subsidiary, Dr. Reddy's Laboratories SA, Switzerland, has received a Complete Response Letter (CRL) from the USFDA for its Biologics License ...

Dr Reddy’s Laboratories ( ($RDY) ) just unveiled an update. On December 31, 2025, Dr. Reddy’s Laboratories disclosed that its wholly owned Swiss ...

AVT03 is a proposed biosimilar candidate to Prolia and Xgeva, developed by Alvotech hf. The application was submitted by Dr ...